Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

The report comes a day after President Trump sent a series of letters to top U.S. healthcare company CEOs insisting that they lower the prices of important treatments. If implemented, this apparent ...

AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Shares of Eli Lilly And Co. (LLY) and Novo Nordisk (NVO) jumped on Friday following reports that the Trump administration is ...

Eli Lilly (NYSE:LLY) stock rose 1.3% and Novo Nordisk (NYSE:NVO) shares jumped 2% Friday morning after The Washington Post ...

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

The trial included over 13,000 people across 30 countries and ran for more than 4.5 years, making it the largest and longest study on tirzepatide so far, the company said ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

US pharma major Eli Lilly has announced top-line results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase III ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

President Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios ...